• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Kestra Medical Technologies Ltd.

    10/7/25 3:49:26 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care
    Get the next $KMTS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    KESTRA MEDICAL TECHNOLOGIES INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    G52441105

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G52441105


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,225,753.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,225,988.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,225,988.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.2 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    G52441105


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,225,988.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,225,988.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    10.2 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    KESTRA MEDICAL TECHNOLOGIES INC
    (b)Address of issuer's principal executive offices:

    3933 LAKE WASHINGTON BLVD NE,SUITE 200,KIRKLAND,WA,USA,98033
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    G52441105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    5225988.00
    (b)Percent of class:

    10.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    5225988.00

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of KESTRA MEDICAL TECHNOLOGIES INC. No one other person's interest in the COMMON STOCK of KESTRA MEDICAL TECHNOLOGIES INC is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:10/06/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:10/06/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $KMTS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KMTS

    DatePrice TargetRatingAnalyst
    3/31/2025$30.00Buy
    BofA Securities
    3/31/2025$29.00Outperform
    Wolfe Research
    3/31/2025$24.00Neutral
    Goldman
    3/31/2025$28.00Buy
    Stifel
    3/31/2025$28.00Overweight
    Wells Fargo
    3/31/2025$27.00Overweight
    Piper Sandler
    More analyst ratings

    $KMTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Commercial Officer Ford Alfred J Jr bought $340,000 worth of shares (20,000 units at $17.00), increasing direct ownership by 68% to 49,412 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:30:46 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Amendment: Officer Umberger Traci S bought $229,500 worth of shares (13,500 units at $17.00), increasing direct ownership by 11% to 134,336 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:17:34 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Director Cohen Raymond W bought $289,000 worth of shares (17,000 units at $17.00) and was granted 10,909 shares, increasing direct ownership by 215% to 40,903 units (SEC Form 4)

    4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/8/25 5:38:22 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kestra Appoints Timothy Moran as Chief Business Officer, Strengthening Leadership Team for Next Stage of Growth

    KIRKLAND, Wash., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Timothy Moran as Chief Business Officer, effective November 3. In this role, Mr. Moran will oversee business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management. "I am pleased to welcome Tim as our Chief Business Officer," said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. "With extensive expertise in cardiac and heart failure innovation, Tim is well positioned to join Kestra at this i

    10/7/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Kestra Showcases Cardiac Recovery System Platform at HFSA 2025, Redefining Sudden Cardiac Arrest Risk Management

    KIRKLAND, Wash., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ: KMTS), a wearable medical device and digital healthcare company, today announced its debut at the 2025 Heart Failure Society of America (HFSA) Annual Scientific Meeting, September 26–29 in Minneapolis, Minnesota. At booth #920, Kestra will feature its Cardiac Recovery System® (CRS) platform, anchored by the ASSURE® Wearable Cardioverter Defibrillator. The CRS platform closes the critical gap in sudden cardiac death protection by pairing protection with actionable insights that support confident care during the high-risk early phase of heart failure recovery. Attendees can explore the CRS platfo

    9/25/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies Appoints Dr. Elizabeth Kwo to Board of Directors

    KIRKLAND, Wash., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Elizabeth Kwo, M.D. as an independent director to its board following her election at the company's annual general meeting of shareholders held earlier this month. "I am pleased to welcome Dr. Kwo to the Kestra board of directors," said Brian Webster, President and CEO of Kestra Medical Technologies. "As a physician, healthcare executive, and entrepreneur, she brings extensive experience building and scaling digital health platforms and advancing data-driven care models to improve patient outcomes.

    9/17/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kestra Medical Technologies Ltd.

    SCHEDULE 13G/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)

    10/7/25 3:49:26 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Kestra Medical Technologies Ltd.

    10-Q - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

    9/12/25 4:17:17 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)

    9/11/25 4:17:04 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Commercial Officer Ford Alfred J Jr bought $340,000 worth of shares (20,000 units at $17.00), increasing direct ownership by 68% to 49,412 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:30:46 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Amendment: Officer Umberger Traci S bought $229,500 worth of shares (13,500 units at $17.00), increasing direct ownership by 11% to 134,336 units (SEC Form 4)

    4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/15/25 4:17:34 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Director Ladone Mary Kay was granted 10,909 shares, increasing direct ownership by 84% to 23,903 units (SEC Form 4)

    4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)

    9/8/25 5:45:01 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Kestra Medical Technologies with a new price target

    BofA Securities initiated coverage of Kestra Medical Technologies with a rating of Buy and set a new price target of $30.00

    3/31/25 8:54:18 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Wolfe Research initiated coverage on Kestra Medical Technologies with a new price target

    Wolfe Research initiated coverage of Kestra Medical Technologies with a rating of Outperform and set a new price target of $29.00

    3/31/25 8:13:51 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on Kestra Medical Technologies with a new price target

    Goldman initiated coverage of Kestra Medical Technologies with a rating of Neutral and set a new price target of $24.00

    3/31/25 8:13:51 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    $KMTS
    Leadership Updates

    Live Leadership Updates

    View All

    Kestra Appoints Timothy Moran as Chief Business Officer, Strengthening Leadership Team for Next Stage of Growth

    KIRKLAND, Wash., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Timothy Moran as Chief Business Officer, effective November 3. In this role, Mr. Moran will oversee business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management. "I am pleased to welcome Tim as our Chief Business Officer," said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. "With extensive expertise in cardiac and heart failure innovation, Tim is well positioned to join Kestra at this i

    10/7/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies Appoints Dr. Elizabeth Kwo to Board of Directors

    KIRKLAND, Wash., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Elizabeth Kwo, M.D. as an independent director to its board following her election at the company's annual general meeting of shareholders held earlier this month. "I am pleased to welcome Dr. Kwo to the Kestra board of directors," said Brian Webster, President and CEO of Kestra Medical Technologies. "As a physician, healthcare executive, and entrepreneur, she brings extensive experience building and scaling digital health platforms and advancing data-driven care models to improve patient outcomes.

    9/17/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    $KMTS
    Financials

    Live finance-specific insights

    View All

    Kestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results

    KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period.Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period.Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. "We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter," sai

    9/11/25 4:01:00 PM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies, Ltd. to Report First Quarter Fiscal 2026 Financial Results

    KIRKLAND, Wash., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report first quarter fiscal 2026 financial results on Thursday, September 11. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital h

    8/28/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care

    Kestra Medical Technologies Wins 2025 Top Workplaces Industry Award, A National Recognition

    KIRKLAND, Wash., July 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, announced today that it is a 2025 Top Workplaces Industry winner by Energage, a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 17-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. Top Workplaces Industry awards celebrate organizations that have built people-first workplace cultures within their sector. The award marks them as an employer of choice for those seeking employment in the industry. "Being

    7/17/25 8:00:00 AM ET
    $KMTS
    Medical/Dental Instruments
    Health Care